Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1a First-in-Human Study of Safety and Tolerability of ASV AGEN2017 With QS-21 Stimulon Adjuvant as a Single Agent in Subjects With Solid Tumor at Risk of Relapse Undergoing Observation as SOC Following Complete Surgical Resection

Trial Profile

Phase 1a First-in-Human Study of Safety and Tolerability of ASV AGEN2017 With QS-21 Stimulon Adjuvant as a Single Agent in Subjects With Solid Tumor at Risk of Relapse Undergoing Observation as SOC Following Complete Surgical Resection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2018

At a glance

  • Drugs AutoSynVax (Primary) ; QS 21 (Primary)
  • Indications Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Agenus
  • Most Recent Events

    • 31 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 25 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top